If serotonin dominated the last era of depression research, glutamate is shaping the next one. Glutamate is the brain’s main excitatory messenger, the chemical that does the heavy lifting in learning and memory by helping neurons fire and forge new links. For a long time it was overshadowed in psychiatry. Then a surprising discovery dragged it into the spotlight: a drug acting on the glutamate system could lift severe depression in hours rather than weeks.

That drug is ketamine, long known as an anesthetic and party drug, now repurposed in carefully controlled medical settings. What makes it remarkable is the speed. Traditional antidepressants can take a month to help, a brutal wait for someone in crisis. Ketamine, and a nasal-spray version derived from it, can ease symptoms almost immediately in some people who haven’t responded to anything else. For treatment-resistant depression, that’s a genuine breakthrough.

The mechanism is where things get interesting. Ketamine blocks a particular glutamate receptor, and through a cascade of downstream effects it appears to trigger a burst of synaptic growth. Depression and chronic stress seem to wither the connections between certain neurons; ketamine appears to help regrow them quickly. In other words, the relief may come not from flooding the brain with a feel-good chemical but from physically rebuilding circuitry that stress had pruned away.

There are real caveats. Ketamine’s effects can fade, it carries risks of misuse, and it isn’t a casual prescription. But it has reoriented the whole field toward the idea that fixing depression might mean restoring the brain’s structure, not just tweaking its chemistry. Researchers are now hunting for next-generation drugs that capture the benefit without the baggage. Read more in our glutamate and neurochemistry sections.